Eng Hooi (Cheryl) Tan
BSc (Pharm), MPH, PhD
Postdoctoral Research Assistant in Pharmaco-epidemiological Methods
As a pharmacoepidemiologist, I apply methods to investigate the drug utilisation and comparative effectiveness and safety of medications using routinely collected healthcare data. I am currently involved in a study to assess the comparability of osteoporosis treatment groups via negative control outcomes analysis. I hope to support reliable evidence generation that translates into better patient care.
I completed my PhD at the National University of Singapore (NUS). My thesis explored the detection of drug-induced liver injury in electronic medical records. I obtained my Master of Public Health (MPH) from the University of Sydney and graduated from NUS with a BSc (Pharmacy) as an ASEAN scholar.
My working experience includes practicing as a pharmacist in a tertiary hospital and an oncology centre. While working on my PhD, I was also a research associate managing a randomised controlled trial evaluating the use of SMS reminders to improve medication adherence in women with breast cancer.
I joined NDORMS in June 2020.
Effect of Moderate to High Intensity Aerobic Exercise on Blood Pressure in Young Adults: The TEPHRA open, two-arm, parallel superiority randomized clinical trial
LEESON C., (2022), Eclinicalmedicine
Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.
Kostka K. et al, (2022), Clin epidemiol, 14, 369 - 384
THE IMPACT OF COVID-19 ON POPULATION-LEVEL DRUG UTILIZATION OF ALENDRONATE
Tan EH. et al, (2021), Osteoporosis international, 32, S314 - S315
TREATMENT PATTERNS FOR OSTEOPOROSIS MEDICATIONS IN FIVE EUROPEAN COUNTRIES: A MULTINATIONAL REAL WORLD COHORT ANALYSIS
Robinson DE. et al, (2021), Osteoporosis international, 32, S315 - S315
Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience.
Duarte-Salles T. et al, (2021), Pediatrics, 148